Notable Monday Option Activity: IBM, INCY, CME

Incyte (INCY) saw 9,535 option contracts trade (≈953,500 underlying shares), equal to roughly 46.9% of its one‑month ADV of 2.0M shares, highlighted by 2,059 contracts in the $95 put expiring December 19, 2025 (≈205,900 shares). CME Group (CME) had 9,151 option contracts (≈915,100 shares), about 44.6% of its one‑month ADV of 2.1M shares, led by 4,019 contracts in the $275 call expiring December 12, 2025 (≈401,900 shares). The concentration of volume at these strikes and expirations represents sizeable intraday flow that could affect short‑term liquidity, implied volatility and price action around those strike levels.

Analysis

Market structure: The oversized options flow (INCY ~953,500 notional shares = ~46.9% ADV; CME ~915,100 = ~44.6% ADV) implies non-trivial directional positioning rather than routine retail activity. Market-makers delta-hedging the INCY $95 puts will tend to sell ~200k shares into the market initially, pressuring the equity and lifting implied volatility and put skew; conversely, large CME call demand implies dealer buying of underlying or long-gamma exposure that supports CME equity and its volatility-sensitive revenue mix.

Risk assessment: Near-term (days–weeks) the primary risk is hedging-driven price moves and IV repricing; mid-term (1–6 months) risks diverge—INCY faces regulatory/clinical tail risk (FDA decisions or trial readouts) that could move >30–50%, while CME faces macro/market-volume risk tied to Fed policy and liquidity; long-term to Dec 2025 expiry, both trades can suffer from being mis-specified (flow could be complex spreads, not naked puts/calls).

Trade implications: Tactical plays: for INCY, prefer defined-risk bearish exposure — buy Dec19,2025 95/75 put spread sized to 1% portfolio with 30% max premium stop and target 2.5x if clinical/regulatory slide occurs; for CME, take long exposure — buy Dec12,2025 275/315 call spread (1–2% portfolio) or 1–2% outright equity long with stop at -10% and target +30–40% into higher volumes. Pair trade: long CME / short INCY 1:1 notional to express market-structure vs biotech idiosyncrasy.

Contrarian angles: The consensus may mistake high volume for pure directional bets—flows can be risk reversals or institutional collars; if INCY fundamentals are intact, forced selling could create a 10–20% buying opportunity—consider accumulating on a >15% intraday drop. Conversely, CME call froth could be overbought if market volumes slow; consider selling a portion of long call exposure after a 10–15% move up to monetize skew compression.

Key Decisions for Investors

• Establish a defined-risk bearish position in INCY: buy Dec 19, 2025 95/75 put spread sized to ~1% of portfolio notional; set a 30% premium stop and target 2.5x return or exit on positive clinical/FDA news within 6–12 months.
• Establish a bullish position in CME: buy Dec 12, 2025 275/315 call spread sized 1–2% of portfolio (or buy 1–2% equity with 10% stop); take profits at +30–40% or trim by 50% after a 10–15% rally to lock in skew compression.
• Execute a relative-value pair: long CME / short INCY 1:1 notional (equal dollar) as a hedge against market-volume-driven upside in exchanges versus biotech idiosyncratic downside; rebalancing window every 4–6 weeks or on major catalysts.